Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers

Susan H. Wei, Chuan Mu Chen, Gordon Strathdee, Jaturon Harnsomburana, Chi Ren Shyu, Farahnaz Rahmatpanah, Huidong Shi, Shu Wing Ng, Pearlly S. Yan, Kenneth P. Nephew, Robert Brown, Tim Hui Ming Huang

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease. Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas. Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 (P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR. Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)2246-2252
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number7
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Microarray Analysis
Epigenomics
Methylation
Disease-Free Survival
Carcinoma
CpG Islands
Neoplasms
Drug Therapy
DNA Methylation
Ovarian Neoplasms
Cluster Analysis
Research Design
Recurrence
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wei, S. H., Chen, C. M., Strathdee, G., Harnsomburana, J., Shyu, C. R., Rahmatpanah, F., ... Huang, T. H. M. (2002). Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clinical Cancer Research, 8(7), 2246-2252.

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. / Wei, Susan H.; Chen, Chuan Mu; Strathdee, Gordon; Harnsomburana, Jaturon; Shyu, Chi Ren; Rahmatpanah, Farahnaz; Shi, Huidong; Ng, Shu Wing; Yan, Pearlly S.; Nephew, Kenneth P.; Brown, Robert; Huang, Tim Hui Ming.

In: Clinical Cancer Research, Vol. 8, No. 7, 01.01.2002, p. 2246-2252.

Research output: Contribution to journalArticle

Wei, SH, Chen, CM, Strathdee, G, Harnsomburana, J, Shyu, CR, Rahmatpanah, F, Shi, H, Ng, SW, Yan, PS, Nephew, KP, Brown, R & Huang, THM 2002, 'Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers', Clinical Cancer Research, vol. 8, no. 7, pp. 2246-2252.
Wei, Susan H. ; Chen, Chuan Mu ; Strathdee, Gordon ; Harnsomburana, Jaturon ; Shyu, Chi Ren ; Rahmatpanah, Farahnaz ; Shi, Huidong ; Ng, Shu Wing ; Yan, Pearlly S. ; Nephew, Kenneth P. ; Brown, Robert ; Huang, Tim Hui Ming. / Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 7. pp. 2246-2252.
@article{d88ddbb71e0c4bcfb152944e3b1303cf,
title = "Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers",
abstract = "Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease. Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas. Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 (P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR. Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.",
author = "Wei, {Susan H.} and Chen, {Chuan Mu} and Gordon Strathdee and Jaturon Harnsomburana and Shyu, {Chi Ren} and Farahnaz Rahmatpanah and Huidong Shi and Ng, {Shu Wing} and Yan, {Pearlly S.} and Nephew, {Kenneth P.} and Robert Brown and Huang, {Tim Hui Ming}",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "2246--2252",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers

AU - Wei, Susan H.

AU - Chen, Chuan Mu

AU - Strathdee, Gordon

AU - Harnsomburana, Jaturon

AU - Shyu, Chi Ren

AU - Rahmatpanah, Farahnaz

AU - Shi, Huidong

AU - Ng, Shu Wing

AU - Yan, Pearlly S.

AU - Nephew, Kenneth P.

AU - Brown, Robert

AU - Huang, Tim Hui Ming

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease. Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas. Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 (P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR. Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.

AB - Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease. Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas. Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 (P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR. Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0035992386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035992386&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 2246

EP - 2252

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -